Literature DB >> 7334461

The pharmacokinetics of penicillamine in a female mongrel dog.

R F Bergstrom, R D Kay, J G Wagner.   

Abstract

The pharmacokinetic parameters of D-penicillamine were investigated by administering four intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg in man. The pharmacokinetics of D-penicillamine demonstrated nonlinearity in the dog. There was more than proportional increase in the area under the whole blood concentration curve for an increase in the bolus intravenous dose. The steady state whole blood, plasma, and packed cells levels of penicillamine were increased more than proportionately for an increase in the intravenous infusion rate. Total body clearance of penicillamine was decreased by increasing the dose or the infusion rate of penicillamine. Correspondingly, the estimated half-life of unchanged penicillamine in the whole blood was decreased for increased intravenous bolus doses. The renal clearance of penicillamine was nonlinear, decreasing with time during the bolus experiments and increasing at higher infusion rates. The nonrenal clearance was decreased at higher infusion rates, suggesting that a saturable nonrenal elimination process exists for penicillamine in the dog. The nonlinearities that were observed in the dog, if also present in man, may be responsible in part for the dose related side effects reported clinically for penicillamine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334461     DOI: 10.1007/bf01061028

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  27 in total

1.  Colorimetric estimation of penicillamine.

Authors:  P R PAL
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

3.  [Pharmacokinetic studies after oral application of radioactively labelled D-penicillamine].

Authors:  K Patzschke; L Wegner; H Kaller; F A Horster
Journal:  Z Rheumatol       Date:  1977 Mar-Apr       Impact factor: 1.372

4.  Controlled trial of D(-)penicillamine in severe rheumatoid arthritis.

Authors: 
Journal:  Lancet       Date:  1973-02-10       Impact factor: 79.321

5.  [Pharmacokinetics and metabolism of D- and L-penicillamine. 3. Absorption, excretion, and metabolism].

Authors:  A Ruiz-Torres; I Kürten
Journal:  Arzneimittelforschung       Date:  1974-09

6.  Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease.

Authors:  K Gibbs; J M Walshe
Journal:  Q J Med       Date:  1971-04

7.  Quantitative determination of biologically important thiols and disulfides by gas-liquid chromatography.

Authors:  E Jellum; V A Bacon; W Patton; W Pereira; B Halpern
Journal:  Anal Biochem       Date:  1969-10-01       Impact factor: 3.365

8.  High-performance liquid chromatographic determination of penicillamine in whole blood, plasma, and urine.

Authors:  R F Bergstrom; D R Kay; J G Wagner
Journal:  J Chromatogr       Date:  1981-03-13

9.  [Pharmacokinetic and metabolism of D- and L-penicillamine. 2. Distribution of D- and L-penicillamine-14C in the rat organism after oral administration].

Authors:  A Ruiz-Torres
Journal:  Arzneimittelforschung       Date:  1974-07

10.  Clinical evaluation of D-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis.

Authors:  Y Shiokawa; Y Horiuchi; M Honma; T Kageyama; T Okada; T Azuma
Journal:  Arthritis Rheum       Date:  1977 Nov-Dec
View more
  8 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

3.  Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

Authors:  E Lipka; I D Lee; P Langguth; H Spahn-Langguth; E Mutschler; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

4.  Absorption of flurbiprofen in the fed and fasted states.

Authors:  J B Dressman; R R Berardi; G H Elta; T M Gray; P A Montgomery; H S Lau; K L Pelekoudas; G J Szpunar; J G Wagner
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

5.  Efficacy of D-penicillamine, a sequestering acetaldehyde agent, in the prevention of alcohol relapse-like drinking in rats.

Authors:  Alejandro Orrico; Lucía Hipólito; María José Sánchez-Catalán; Lucía Martí-Prats; Teodoro Zornoza; Luis Granero; Ana Polache
Journal:  Psychopharmacology (Berl)       Date:  2013-03-21       Impact factor: 4.530

6.  ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs.

Authors:  Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

Review 7.  D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective.

Authors:  Michela Pugliese; Vito Biondi; Enrico Gugliandolo; Patrizia Licata; Alessio Filippo Peritore; Rosalia Crupi; Annamaria Passantino
Journal:  Antibiotics (Basel)       Date:  2021-05-28

Review 8.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.